Thalidomide and discoid lupus erythematosus: case series and review of literature
Authors:
Open Access
- 16 March 2022
- journal article
- research article
- Published by BioExcel in Drugs in Context
- Vol. 11, 1-10
Abstract
The anti-inflammatory drug, thalidomide, is often administered off-label especially in dermatology patients with diseases refractory to different medications. The drug’s mechanism of action is not well understood but clinical evidence suggests an immunomodulatory function. Although this drug is a useful tool for several dermatoses, there are associations between its use and neurotoxic and teratogenic side effects. Consequently, it is reserved only for severe and refractory cases. Herein, we present a review about thalidomide focusing on its application in dermatology, particularly on discoid lupus erythematosus (DLE) treatment. We analyzed four cases of people who had a regression of DLE with a dosage of 50 mg thalidomide. Patients were followed to determine the conditions treated with thalidomide, dosage, efficacy, duration of treatment, side effects, adverse events and follow-up. A low dose of 50 mg/day induced a notable and rapid improvement within 1–2 months of treatment and no side effects have been reported so far. We report four cases of DLE treated previously with the most common immunomodulatory agents with no results and finally successfully treated with thalidomide. In all four patients, despite a low dose of 50 mg/day, a notable and rapid improvement was obtained within a few months of treatment with no side effects. Notwithstanding the small cohort size, our experience confirms the efficacy of thalidomide for the treatment of DLE.Keywords
This publication has 67 references indexed in Scilit:
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals of the Rheumatic Diseases, 2012
- Cutaneous lupus erythematosus: Update of therapeutic optionsJournal of the American Academy of Dermatology, 2011
- Cutaneous Lupus ErythematosusAmerican Journal of Clinical Dermatology, 2009
- Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patientsBritish Journal of Dermatology, 2009
- Thalidomide: dermatological indications, mechanisms of action and side-effectsBritish Journal of Dermatology, 2005
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide may impede cell migration in primates by down-regulating integrin β-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosisMedical Hypotheses, 1997
- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential usesJournal of the American Academy of Dermatology, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993